Relevance of Immune Infiltration and Clinical Outcomes in Pancreatic Ductal Adenocarcinoma Subtypes. 2020

Rong Liu, and Ya-Zhou Liao, and Wei Zhang, and Hong-Hao Zhou
Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, China.

OBJECTIVE Pancreatic ductal adenocarcinoma (PDAC) is a lethal cancer with high heterogeneity and dismal survival rates. Tumor immune microenvironment plays a critical role in sensitive to chemotherapy and prognosis. Herein, we determined the relevance of the composition of tumor-infiltrating immune cells to clinical outcomes in PDACs, and we evaluated these effects by molecular subtype. METHODS Data of 1,274 samples from publically available datasets were collected. Molecular subtypes were predicted with support vector machine. Twenty-two subsets of immune cells were estimated with CIBERSORTx. The associations between each cell subset and overall survival (OS), relapse free survival (RFS), and complete response (CR) to chemotherapy were evaluated, modelling cellular proportions as quartiles. RESULTS An immune-related cluster was identified with unsupervised hierarchical clustering of hallmark pathways. Of the immune cells investigated, M0 macrophages emerged as closely associated with worse OS (HR =1.23, 95% CI = 1.15-1.31, p=1.57×10-9) and RFS (HR = 1.14, 95% CI =1.04-1.25, p=2.93×10-3), regardless of molecular subtypes. The CD8+ T cells conferred favorable survival. The neutrophils conferred poor OS overall (HR=1.17, 95% CI=1.10-1.23, p=1.74×10-7) and within the classical subtype. In the basal-like subtype, activated mast cells were associated with worse OS. Consensus clustering revealed six immune subgroups with distinct survival patterns and CR rates. The higher expression of PD1 was associated with better OS. CONCLUSIONS The immune cellular composition infiltrate in PDAC are likely to have effects on prognosis. Further exploration of the cellular immune response has the potential to identify candidates for immunotherapy.

UI MeSH Term Description Entries

Related Publications

Rong Liu, and Ya-Zhou Liao, and Wei Zhang, and Hong-Hao Zhou
August 2016, BMC cancer,
Rong Liu, and Ya-Zhou Liao, and Wei Zhang, and Hong-Hao Zhou
July 2020, Journal of advanced research,
Rong Liu, and Ya-Zhou Liao, and Wei Zhang, and Hong-Hao Zhou
July 2023, Current gene therapy,
Rong Liu, and Ya-Zhou Liao, and Wei Zhang, and Hong-Hao Zhou
December 2017, The Lancet. Oncology,
Rong Liu, and Ya-Zhou Liao, and Wei Zhang, and Hong-Hao Zhou
March 2014, Clinical and translational gastroenterology,
Rong Liu, and Ya-Zhou Liao, and Wei Zhang, and Hong-Hao Zhou
February 2021, Journal of cancer research and clinical oncology,
Rong Liu, and Ya-Zhou Liao, and Wei Zhang, and Hong-Hao Zhou
January 2022, Frontiers in oncology,
Rong Liu, and Ya-Zhou Liao, and Wei Zhang, and Hong-Hao Zhou
September 2021, International immunopharmacology,
Rong Liu, and Ya-Zhou Liao, and Wei Zhang, and Hong-Hao Zhou
January 2022, Frontiers in oncology,
Rong Liu, and Ya-Zhou Liao, and Wei Zhang, and Hong-Hao Zhou
January 2021, Frontiers in immunology,
Copied contents to your clipboard!